Core Viewpoint - Andy Su is a leading global producer of animal nutrition additives, with a strong focus on research, production, and sales, and a differentiated strategy based on a "dual pillar" approach [1] Group 1: Business Performance - In Q3 2025, Andy Su reported revenue of 12.931 billion yuan, ranking 3rd in the industry, surpassing the industry average of 3.571 billion yuan and the median of 1.238 billion yuan [2] - The company's net profit for the same period was 999.2 million yuan, ranking 4th in the industry, above the industry average of 539 million yuan and the median of 124 million yuan [2] - Functional products accounted for 76.07% of total revenue, while specialty products made up 23.93% [2] Group 2: Financial Ratios - As of Q3 2025, Andy Su's debt-to-asset ratio was 32.69%, higher than the previous year's 28.81% and the industry average of 28.46% [3] - The gross profit margin for Q3 2025 was 27.87%, down from 30.58% in the previous year and below the industry average of 28.77% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.46% to 32,200 [5] - The average number of circulating A-shares held per shareholder increased by 1.48% to 83,300 [5] Group 4: Strategic Insights - Andy Su is recognized as a global leader in the methionine industry, with ongoing expansion projects in Quanzhou, and plans to enhance solid methionine production capacity [6] - The specialty products segment is expected to contribute 20% of its revenue from new products by 2026, with further growth anticipated through acquisitions [6] - The company is projected to achieve net profits of 1.6 billion, 1.7 billion, and 2.1 billion yuan for 2025, 2026, and 2027, respectively, with growth rates of 29%, 11%, and 20% [6] Group 5: Market Outlook - The company is expected to maintain its leadership in the methionine market, with ongoing projects to enhance production capacity in both solid and liquid methionine [7] - The diversification of specialty products is a key focus, with initiatives aimed at improving feed digestibility and localizing production [7] - Revenue projections for 2025, 2026, and 2027 are estimated at 17.288 billion, 19.026 billion, and 20.552 billion yuan, respectively, with net profits of 1.714 billion, 1.944 billion, and 2.216 billion yuan [7]

Core Insights - The company reported a revenue of 12.931 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 13.67% [1] - The net profit attributable to shareholders was 990 million yuan, showing a year-on-year decline of 1.29% [1] - The basic earnings per share stood at 0.37 yuan [1] Financial Performance - The gross profit margin for the first three quarters was 27.87%, down 2.72 percentage points year-on-year [2] - The net profit margin was 7.67%, a decrease of 1.15 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin was 26.83%, down 2.39 percentage points year-on-year and 0.32 percentage points quarter-on-quarter [2] - The net profit margin for Q3 was 5.67%, down 3.96 percentage points year-on-year and 0.89 percentage points quarter-on-quarter [2] Expense Analysis - Total operating expenses for the period were 2.043 billion yuan, an increase of 48.795 million yuan year-on-year [2] - The expense ratio was 15.80%, a decrease of 1.73 percentage points from the previous year [2] - Sales expenses increased by 12.77%, while management expenses decreased by 1.73%, R&D expenses decreased by 6.10%, and financial expenses decreased by 56.75% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 32,200, a decrease of 477 from the end of the first half of the year, representing a decline of 1.46% [2] - The average market value per shareholder decreased from 791,600 yuan to 783,400 yuan, a decline of 1.04% [2] Company Overview - The company, Blue Star Adisseo Co., Ltd., is located in Beijing and was established on May 31, 1999, with its listing date on April 20, 2000 [3] - The main business involves the research, production, and sales of animal nutrition additives, with functional products accounting for 76.07% and specialty products for 23.93% of revenue [3] - The company is classified under the basic chemicals industry, specifically in food and feed additives [3]

独立董事候选人声明与承诺 本人孙志祥，巳充分了解并同意由提名人蓝星安迪苏股份有 限公司董事会提名为蓝星安迪苏股份有限公司第九届董事会独 立董事候选人。本人公开声明， 本人具备独立董事任职资格， 保 证不存在任何影响本人担任蓝星安迪苏股份有限公司独立董事 独立性的关系， 具体声明并承诺如下： 一 、本人具备上市公司运作的基本知识， 熟悉相关法律、 行 政法规、部门规章及其他规范性文件，具有5年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 本人巳经参加培训并取得证券交易所认可的相关培训证明 材料。 二、 本人任职资格符合下列法律 、行政法规和 部门规章以及 公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； (八)中国证监会《证券基金经营机构董事、监事、高级管 理人员及从业人员监督管理办法》等的相关规定(如适用); （二） 《中华人民共和国公务员法》关于公务员兼任职务的 规定（如适用）； （三）中国证监会 《上市公司独立董事管理办法》、上海证 券交易所自律 监管规则以及公司章程有关独立董事任职资格 和 条件的相关规定； （四）中共中夹纪委、中共中夹组织部《关于 ...

独立董事提名人声明与承诺 提名人蓝星安迪苏股份有限公司董事会，现提名孙志祥为蓝 星安迪苏股份有限公司第九届董事会独立董事候选人，并已充分 了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况。被提名人已同意出任蓝星安迪 苏股份有限公司第九届董事会独立董事候选人（参见该独立董事 候选人声明）。提名人认为，被提名人具备独立董事任职资格， 与蓝星安迪苏股份有限公司之间不存在任何影响其独立性的关 系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （四）中共 ...

证券代码：600299 证券简称：安迪苏 公告编号：2025-048 蓝星安迪苏股份有限公司 2025 年第三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"安迪苏"或"公司"）根据上海证券交易 所发布的《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露 第十 四号——食品制造》的要求，现将公司 2025 年第三季度主要经营数据披露如下： 一、 2025 年第三季度主要经营数据 (一) 按产品类别： 单位：元 币种：人民币 | | 营业收入 | | | | | --- | --- | --- | --- | --- | | 分产品 2025 | 年第三季度 | 2024 年第三季度 | 同比变动 | (%) | | 功能性产品 | 3,275,298,626 | 3,105,903,653 | | 5.45 | | 特种产品 | 1,143,676,282 | 1,009,095,503 | | 13.34 | | 合计 | 4,418,974,908 | 4 ...

蓝星安迪苏股份有限公司 证券代码：600299 证券简称：安迪苏 公告编号：2025-050 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 蓝星安迪苏股份有限公司（以下简称"公司"）于 2025 年 10 月 31 日披露公 司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三 季度经营成果、财务状况，公司计划于 2025 年 11 月 14 日下午 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频直播和网络互动形式召开，公司将针对 2025 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 11 月 14 日 下午 15:00-16:00 1 董事长兼总经理（CEO）：郝志刚先生 独立董事：刘昕先生 副总经理兼 ...

特此公告。 蓝星安迪苏股份有限公司董事会 证券代码：600299 证券简称：安迪苏 编号：2025-047 蓝星安迪苏股份有限公司 关于增补独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为提升蓝星安迪苏股份有限公司（以下简称"公司"）内部治理水平，保 证董事会的规范运作，根据《蓝星安迪苏股份有限公司章程》规定，公司拟增 补一名独立董事。经公司提名委员会提名并审核通过独立董事候选人孙志祥女 士（简历附后）的任职资格，公司于 2025 年 10 月 30 日召开的第九届董事会第 九次会议审议并通过了关于《增补第九届董事会独立董事》的议案，增补孙志 祥女士为公司第九届董事会独立董事候选人，任期自股东会审议通过之日起至 第九届董事会任期届满之日止。孙志祥女士的任职资格尚需上海证券交易所审 核，尚需提交公司股东会审议。 | | 生于 1967 年，汉族，中国籍，复旦大学法学学士，复旦大学 | | --- | --- | | | 国际经济法学硕士，美国哈佛大学高级访问学者。孙女士从事 | | | 法律咨询工作超过 年，在 ...

证券代码：600299 证券简称：安迪苏 公告编号：2025-049 蓝星安迪苏股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第四次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 1 日 14 点 00 分 召开地点：北京市朝阳区北土城西路 9 号蓝星大厦会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 1 日 1 股东会召开日期：2025年12月1日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 至2025 年 12 月 1 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9 ...

证券代码：600299 证券简称：安迪苏 公告编号：2025-046 蓝星安迪苏股份有限公司 第九届董事会第九次会议 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"公司"）第九届董事会第九次会议于 2025 年 10 月 30 日以通讯表决的方式召开。董事会会议通知和材料于 2025 年 10 月 27 日以电子邮件方式发出。会议应参加表决董事 9 人，实际参加表决董事 9 人。 本次会议符合《中华人民共和国公司法》和《蓝星安迪苏股份有限公司章程》的 有关规定。本次会议由公司董事长郝志刚先生召集，公司部分高管列席会议。 参加会议的董事表决通过以下议案： 1. 审议通过关于《2025 年第三季度报告》的议案 审计、风险及合规委员会委员由林兆荣先生（主任委员）、刘昕先生、孙岩 峰先生调整为林兆荣先生（主任委员）、孙志祥女士、孙岩峰先生。该议案 自股东会审议通过关于《增补第九届董事会独立董事》的议案后生效。 《2025 年第三季度报告》内容详见上海证券交易所网站：www.sse.com. ...

Financial Performance - The company's operating revenue for Q3 2025 was CNY 4,418,974,908, representing a year-on-year increase of 7.39%[3] - The total profit for the period was CNY 354,353,219, a decrease of 30.89% compared to the same period last year[3] - The net profit attributable to shareholders was CNY 250,201,793, down 36.77% year-on-year[3] - The basic earnings per share for the period was CNY 0.09, reflecting a decrease of 40.00% compared to the previous year[3] - Total operating revenue for the first three quarters of 2025 reached CNY 12,931,042,871, an increase of 13.6% compared to CNY 11,375,947,704 in the same period of 2024[17] - Operating profit for the first three quarters of 2025 was CNY 1,375,934,261, slightly down from CNY 1,378,171,752 in 2024, indicating a stable performance[18] - Net profit attributable to shareholders of the parent company for the first three quarters of 2025 was CNY 990,385,122, compared to CNY 1,003,279,525 in 2024, reflecting a decrease of 1.3%[18] - The company reported a comprehensive income total of CNY 1,857,785,945 for the first three quarters of 2025, significantly up from CNY 950,427,428 in 2024[19] Assets and Liabilities - Total assets at the end of the period amounted to CNY 25,174,272,502, an increase of 13.11% compared to the end of the previous year[4] - As of September 30, 2025, the total assets of the company reached RMB 25,174,272,502, an increase from RMB 22,257,398,577 as of December 31, 2024, representing a growth of approximately 8.6%[13] - The company's current assets totaled RMB 7,319,268,891, up from RMB 6,395,939,923, indicating an increase of about 14.4% year-over-year[14] - Total liabilities increased to RMB 8,229,869,392 from RMB 6,687,616,587, representing a growth of about 23%[15] - The company's long-term borrowings rose significantly to RMB 1,889,718,377 from RMB 925,558,489, indicating an increase of approximately 104%[15] - The non-current assets totaled RMB 17,855,003,611, up from RMB 15,861,458,654, reflecting an increase of about 12.5%[14] - The company's equity remained stable at RMB 2,681,901,273, unchanged from the previous period[15] Cash Flow - The company reported a net cash flow from operating activities of CNY 2,284,431,324 for the year-to-date, showing a 2.86% increase[3] - Cash flow from operating activities for the first three quarters of 2025 was CNY 2,284,431,324, slightly higher than CNY 2,220,971,908 in 2024[22] - The company incurred a net cash outflow from investing activities of CNY 2,069,867,110 in the first three quarters of 2025, compared to CNY 1,177,816,244 in 2024, indicating increased investment activities[22] - Cash inflow from financing activities in the first three quarters of 2025 was CNY 946,425,940, a significant increase from CNY 266,097,772 in 2024[22] - Net cash flow from financing activities was $215,369,677, a significant improvement compared to a net outflow of $(722,744,647) in the previous period[23] - Total cash and cash equivalents at the end of the period reached $1,759,751,219, up from $1,334,456,897 year-over-year[23] - The net increase in cash and cash equivalents was $526,115,384, compared to $329,229,338 in the prior year[23] - Cash outflows from financing activities totaled $731,056,263, down from $988,842,419 in the previous period[23] - The impact of exchange rate changes on cash and cash equivalents was $96,181,493, compared to $8,818,321 in the prior year[23] Market Conditions and Strategy - The company plans to continue investing in business growth and R&D innovation despite facing a challenging market environment[8] - The increase in revenue was primarily driven by the rising penetration of liquid methionine and double-digit sales growth in specialty products[8] - The company experienced adverse impacts from rising raw material prices, tariff policies, and a sharp decline in vitamin product prices[8] Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 282,051,876, a decrease from CNY 300,385,838 in 2024, suggesting a potential shift in focus[17] Other Financial Metrics - The weighted average return on net assets was 1.48%, a decrease of 3.29 percentage points from the previous year[4] - The cash and cash equivalents increased to RMB 1,759,751,219 from RMB 1,265,778,795, reflecting a growth of approximately 39%[13] - Accounts receivable rose to RMB 2,093,738,151, compared to RMB 1,969,896,420, marking an increase of about 6.3%[14] - Inventory levels increased to RMB 2,476,884,888 from RMB 2,428,174,242, which is an increase of approximately 2%[14] - The company reported a significant increase in other receivables, which rose to RMB 167,468,982 from RMB 90,753,937, marking an increase of approximately 84.5%[14] - The total equity attributable to shareholders of the parent company rose to CNY 16,912,994,342 in 2025, up from CNY 15,542,390,570 in 2024, indicating improved shareholder value[16]